Avelumab Plus Autologous Dendritic Cell Vaccine in Pre-treated Metastatic Colorectal Cancer Patients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

March 12, 2018

Primary Completion Date

June 30, 2019

Study Completion Date

October 5, 2020

Conditions
Colorectal Carcinoma
Interventions
DRUG

Avelumab

"Autologous Dendritic Cells vaccine: A dose of ADC at days 1, 14, 28, 42 and 56 (total of 5 doses), and thereafter every 6 months until disease progression (maximum of 6 additional doses) or unacceptable toxicity.~Avelumab will be administered intravenously at a dose of 10 mg per kilogram of body weight, every 14 days until disease progression or unacceptable toxicity."

Trial Locations (8)

46009

Hospital Universitario y Politécnico La Fe, Valencia

50009

Hospital Universitario Miguel Servet, Zaragoza

08024

Hospital Clínic Barcelona, Barcelona

Hospital Universitario Vall d'Hebron, Barcelona

Unknown

Hospital Universitario La Paz, Madrid

Hospital Universitario Puerta de Hierro, Madrid

Instituto Valenciano de Oncología, Valencia

Hospital Clínico Universitario Lozano Blesa, Zaragoza

All Listed Sponsors
lead

Grupo Espanol Multidisciplinario del Cancer Digestivo

OTHER

NCT03152565 - Avelumab Plus Autologous Dendritic Cell Vaccine in Pre-treated Metastatic Colorectal Cancer Patients | Biotech Hunter | Biotech Hunter